The Top Ten Global In-Vitro Diagnostics Companies: Positioning, performance and SWOT analyses

July 3, 2009 - PRLog -- The in-vitro diagnostics (IVD) market continues to grow at a steady pace, driven by new fields such as molecular diagnostics and a growing consumer awareness surrounding disease management. There is also an increasing focus on emerging markets, where healthcare infrastructures are improving. The industry is highly competitive and continues to witness large scale consolidation. Major in-vivo players are beginning to enter the in-vitro market and the regulatory environment is becoming even more stringent, increasing the time to approval for new products.

‘The Top 10 Global In-Vitro Diagnostics Companies’ is a report published explores the global competitive landscape of the IVD industry. This report analyses the size and structure of the market and identifies the latest developments in service offerings, new technologies, strategic approaches and competitive dynamics amongst leading companies. This report assesses the opportunities and threats facing the top 10 IVD companies in the future, and examines their current structure, financial performance, growth strategies and R&D activity. Growth forecasts for key products and regions are also provided.

Key Findings

The global in-vitro diagnostics (IVD) market is forecast to grow at a rate of 6% to reach $50.0bn in 2012. The market has been growing at a rate of 5-6% in recent years, reaching a value of $36.5bn in 2007.

Roche is the largest player in the market with a share of 20%. It is followed by Siemens and Abbott, who both hold 12% of the market. The IVD market is highly consolidated, with the top ten players holding close to 80% market share.

Molecular diagnostics, diabetes care, and emerging markets are the key growth drivers of the IVD industry. Theranostics is an emerging field with great promise and a number of players are making extensive efforts in the area.

Abbott’s IVD revenues increased by 10.8% to reach $4.4bn in 2007. However, Abbott’s diagnostics margins have been falling and it has recently announced a cost-cutting plan to improve the operating margin of its diagnostics unit. Abbott has also been faced with regulatory issues, with its diagnostics business coming under FDA supervision.

A number of large in-vivo players have entered the IVD market recently, signalling the convergence of the two diagnostic fields. Siemens Healthcare is a prominent example of this trend, following their acquisition of DPC, Bayer Diagnostics and Dade Behring.

Use this report to...

   * Compare the performances of the top 10 IVD companies across key business segments and geographies with this report’s analysis of Roche Diagnostics, Siemens Healthcare, Abbott, J&J, Beckman Coulter, Becton Dickinson, bioMerieux, Bayer Diabetes, Sysmex and Bio-Rad.
   * Understand the market dynamics shaping the global IVD industry, forecast key growth areas by product/region and identify deal-making patterns across clinical trials phases and key therapeutic areas.
   * Evaluate the future prospects of major IVD players with this report’s examination of R&D expenditure, M&A activity, growth strategies and SWOT analyses for each of the top 10 companies.
   * Measure the progress of other leading IVD companies by analysing the financial performances of Inverness, Chiron (Novartis), Olympus, Gen Probe, Hologic/Cytyc, Qiagen, Arkray, DiaSorin, Radiometer, Werfen.

Explore issues including...

Industry consolidation. The IVD market is consolidating further due to a large number of smaller companies striving to increase their market share through M&A activity. Big Pharma is also entering the IVD market through acquisitions.

Growth of molecular diagnostics. Molecular diagnostics is one of the fastest growing segments of the IVD market and is expected to grow at a CAGR of 14% over the next five years.

Stringent regulatory environment. Regulation within the IVD market is becoming increasingly stringent, particularly in the US where the FDA is intensifying its scrutiny on diagnostics companies.

Emergence of theranostics. Advances in the field of genomics are leading to the emergence of theranostics and personalized healthcare. Theranostics uses diagnostic testing to tailor disease treatment to individual needs through the application of molecular diagnostics. A number of players are currently conducting R&D and launching new products in the fields of theranostics and personalized healthcare.

For more information, please visit :
http://www.aarkstore.com/reports/The-Top-Ten-Global-In-Vi...
Or email us at press@aarkstore.com or call +919272852585.

# # #

Aarkstore Enterprise specializes in providing business information on market research reports, books, magazines, conference at competitive prices, and strive to provide excellent and innovative service to our customers.